Scarica l'app Stockscreener
15.74
6.86%
1.01
Dopo l'orario di chiusura:
15.97
0.23
+1.46%
Precedente Chiudi:
$14.73
Aprire:
$14.8
Volume 24 ore:
5.08M
Relative Volume:
2.20
Capitalizzazione di mercato:
$1.36B
Reddito:
$139.71M
Utile/perdita netta:
$-209.36M
Rapporto P/E:
-5.3176
EPS:
-2.96
Flusso di cassa netto:
$-160.60M
1 W Prestazione:
+26.12%
1M Prestazione:
+70.90%
6M Prestazione:
+5.50%
1 anno Prestazione:
-21.14%
Intervallo 1D:
$14.80
$15.98
Intervallo di 1 settimana:
$12.10
$15.98
Portata 52W:
$8.58
$22.50
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Nome
Syndax Pharmaceuticals Inc
Settore
Industria
Telefono
781-419-1400
Indirizzo
730 THIRD AVENUE, NEW YORK, MA
Confronta SNDX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
15.74 | 1.27B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-05 | Reiterato | BTIG Research | Buy |
| 2025-07-10 | Iniziato | Goldman | Buy |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-06-28 | Iniziato | Jefferies | Buy |
| 2024-01-31 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | Iniziato | Mizuho | Buy |
| 2023-10-25 | Iniziato | BofA Securities | Buy |
| 2023-10-11 | Iniziato | Goldman | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-11 | Iniziato | Guggenheim | Buy |
| 2023-04-17 | Ripresa | BTIG Research | Buy |
| 2023-01-31 | Iniziato | Stifel | Buy |
| 2023-01-03 | Iniziato | JP Morgan | Overweight |
| 2022-07-28 | Ripresa | B. Riley Securities | Buy |
| 2022-04-11 | Iniziato | H.C. Wainwright | Buy |
| 2022-02-15 | Iniziato | Goldman | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-05-25 | Iniziato | Citigroup | Buy |
| 2021-02-18 | Iniziato | B. Riley Securities | Buy |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | Downgrade | Citigroup | Buy → Neutral |
| 2020-05-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-13 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-01-04 | Iniziato | Robert W. Baird | Outperform |
| 2018-01-05 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | Iniziato | FBR & Co. | Outperform |
| 2017-03-02 | Iniziato | Instinet | Buy |
| 2016-10-07 | Iniziato | Guggenheim | Buy |
| 2016-03-28 | Iniziato | Citigroup | Buy |
| 2016-03-28 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-03-28 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Syndax Pharmaceuticals Inc Borsa (SNDX) Ultime notizie
Why Syndax Pharmaceuticals Inc. stock attracts strong analyst attention2025 Historical Comparison & Weekly Top Gainers Alerts - thegnnews.com
Syndax jumps after Q2 beat; Citi issues upside catalyst watch - MSN
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Up 4.4%Time to Buy? - MarketBeat
Will Syndax Pharmaceuticals Inc. outperform tech stocksJuly 2025 Setups & Capital Efficiency Focused Ideas - sundaytimes.kr
Can Syndax Pharmaceuticals Inc. deliver consistent dividendsJuly 2025 Selloffs & Fast Moving Market Watchlists - thegnnews.com
Aigen Investment Management LP Acquires Shares of 24,158 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals (SNDX): A Sustainable Growth Story or a Market Overreaction? - AInvest
Syndax Pharmaceuticals (SNDX) Is Up 15.8% After Revenue Surges in Q2 2025 Results Has Sentiment Shifted? - Yahoo Finance
Syndax Skyrockets 8.58%—Is This the Start of a Biotech Breakout? - AInvest
Does Syndax (SNDX) Have the Potential to Rally 158.36% as Wall Street Analysts Expect? - Zacks Investment Research
Syndax Pharmaceuticals: A Tale of Two Drug Launches - AInvest
Syndax Pharmaceuticals: A Tale Of Two Drug Launches (NASDAQ:SNDX) - Seeking Alpha
FDA Priority Review and Revenue Growth Drive Short-Term Upswing for Syndax Pharmaceuticals - Insider Monkey
Syndax Pharmaceuticals' Path to Blockbuster Status: Leveraging FDA Priority Review and Revenue Growth in Oncology - AInvest
Analysts Set Expectations for SNDX Q3 Earnings - MarketBeat
S&E In Brief: Launch Updates And Political Headwinds - insights.citeline.com
What makes Syndax Pharmaceuticals Inc. stock price move sharplyLow Cost High Gain Picks - mustnews.co.kr
Syndax Pharmaceuticals (NASDAQ:SNDX) Upgraded by B. Riley to Strong-Buy Rating - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Analysts Just Made A Massive Upgrade To Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Forecasts - 富途牛牛
Analysts Boost Syndax Pharmaceuticals' Forecasts, Revenue and EPS Estimates Increase - AInvest
Analysts Just Made A Dazzling Upgrade To Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Forecasts - Yahoo Finance
11 Best Short-Term Stocks to Invest in - Insider Monkey
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Up on Better-Than-Expected Earnings - MarketBeat
Syndax Pharmaceuticals Publishes Positive Revumenib Data from BEAT AML Trial - MSN
Citigroup Increases Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $51.00 - MarketBeat
BTIG Research Forecasts Strong Price Appreciation for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Issues Quarterly Earnings Results, Beats Estimates By $0.18 EPS - MarketBeat
Citi Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Announces Target Price $51 - 富途牛牛
Citi Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $51 - 富途牛牛
XTX Topco Ltd Invests $783,000 in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax targets expanded $10B market opportunity with Revuforj and Niktimvo amid accelerating adoption and guidance for stable expenses - MSN
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Syndax Pharmaceuticals Announces Inducement Stock Grants Under NASDAQ Listing Rule 5635(c)(4) - AInvest
Citi Raises Syndax Target to $51, Adds Positive Catalyst Watch - AInvest
Citi ups Syndax target, opens ‘upside catalyst watch’ - Yahoo Finance
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q2 2025 Earnings Call Transcript - Insider Monkey
Three Stocks to Buy Now: Harmony Biosciences, Syndax Pharmaceuticals, and Viper Energy - AInvest
Optimistic Investors Push Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Up 40% But Growth Is Lacking - simplywall.st
Syndax Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Syndax Pharmaceuticals Faces Ongoing and Emerging Business Risks: A Closer Look at SEC Filings - TipRanks
Decoding Syndax Pharmaceuticals Inc (SNDX): A Strategic SWOT Ins - GuruFocus
Citigroup Raises SNDX Price Target Amid "Buy" Rating - AInvest
Syndax Pharmaceuticals’ Earnings Call Highlights Robust Growth - TipRanks
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Beats Revenue Estimates - MSN
Syndax Pharmaceuticals Wins Over Wall Street With Strong Drug Gains - Finimize
Syndax Reports Losses, But Wall Street Still Sees Big Upside - Finimize
Evaluating the High-Growth Potential of Biopharma Innovators in 2025: A Deep Dive into Day One, Beam Therapeutics, and Syndax Pharmaceuticals - AInvest
Syndax Pharmaceuticals Shares Rise After Q2 Results Beat - MarketScreener
Syndax Pharmaceuticals Inc Azioni (SNDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.41%
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):